Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E29.21 EPS (ttm)1.32 Insider Own0.20% Shs Outstand2.44B Perf Week2.83%
Market Cap94.07B Forward P/E14.01 EPS next Y2.75 Insider Trans0.00% Shs Float2.44B Perf Month9.05%
Income3.24B PEG3.25 EPS next Q0.66 Inst Own10.10% Short Float0.33% Perf Quarter-6.18%
Sales41.86B P/S2.25 EPS this Y-89.20% Inst Trans-1.00% Short Ratio1.41 Perf Half Y-9.61%
Book/sh0.74 P/B52.11 EPS next Y-4.64% ROA4.00% Target Price42.72 Perf Year-0.41%
Cash/sh2.75 P/C14.04 EPS next 5Y9.00% ROE189.00% 52W Range34.52 - 44.53 Perf YTD8.71%
Dividend2.01 P/FCF27.49 EPS past 5Y-28.90% ROI8.60% 52W High-13.12% Beta0.98
Dividend %5.21% Quick Ratio0.40 Sales past 5Y0.40% Gross Margin69.30% 52W Low12.08% ATR0.45
Employees99827 Current Ratio0.60 Sales Q/Q4.00% Oper. Margin13.90% RSI (14)73.76 Volatility0.78% 0.99%
OptionableYes Debt/Eq14.71 EPS Q/Q48.80% Profit Margin7.70% Rel Volume0.77 Prev Close38.56
ShortableYes LT Debt/Eq11.05 EarningsFeb 07 Payout167.30% Avg Volume5.67M Price38.69
Recom2.50 SMA205.03% SMA507.83% SMA200-2.91% Volume2,372,327 Change0.34%
Nov-06-17Downgrade Investec Buy → Hold
Oct-26-17Downgrade BofA/Merrill Buy → Neutral
Sep-08-17Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-05-17Downgrade Citigroup Buy → Neutral
May-26-17Upgrade Berenberg Hold → Buy
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-23-18 10:40AM  Drug companies told to do more to tackle 'superbug' crisis Reuters
10:32AM  Novartis on the Street: Analyst Ratings and Recommendations Market Realist
09:03AM  Reading the Estimates for Novartiss Alcon in 4Q17 Market Realist
08:22AM  Is It Time To Sell GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) Based Off Its PE Ratio? Simply Wall St.
Jan-22-18 12:30PM  Why Novavax Stock Is Spiking Today Motley Fool
07:34AM  Johnson & Johnsons Consumer Segment: 4Q17 Estimates Market Realist
Jan-21-18 08:07AM  Better Buy: GlaxoSmithKline plc vs. Eli Lilly Motley Fool
Jan-20-18 03:02AM  Top Picks For Pharma And Biotech Dividend Rockstars Simply Wall St.
Jan-19-18 10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
07:30AM  Amgens Aimovig is Expected to Witness Steady Growth in 2018 Market Realist
Jan-18-18 09:26AM  J&J (JNJ) Hits New 52-Week High: What's Driving the Stock? Zacks
Jan-17-18 02:13PM  Heres Why Neurometrix Inc Rose as Much as 60% Today SmarterAnalyst
11:17AM  Drugmaker GSK cuts back in Africa to hone emerging markets model Reuters
07:25AM  NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell MarketWatch
07:16AM  Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa Bloomberg
07:00AM  NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology GlobeNewswire
Jan-16-18 11:10AM  What does GlaxoSmithKline plcs (LON:GSK) Balance Sheet Tell Us Abouts Its Future? Simply Wall St.
Jan-15-18 09:05AM  What Are Insys Therapeutics Top Priorities? Market Realist
08:24AM  Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion Zacks
Jan-12-18 05:20PM  Whats behind Insys Therapeutics Legal Tangles? Market Realist
03:50PM  A Look at Insys Therapeutics Financial Performance Market Realist
02:17PM  What Analysts Recommend for Insys Therapeutics and Peers Market Realist
08:00AM  GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older PR Newswire
07:41AM  Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference Zacks
Jan-11-18 09:01AM  AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU Zacks
Jan-10-18 03:23PM  Teva Stock Has Risen Significantly since November Lows: Whats Next? Market Realist
09:36AM  Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar Zacks
09:05AM  Key Risks Facing Mylan in January 2018 Market Realist
Jan-09-18 05:04PM  Emergent Down on '18 View, Posts Preliminary '17 Results Zacks
03:36PM  GSK CEO says looking at Pfizer consumer business, but not a priority Reuters
03:16PM  GSK CEO says looking at Pfizer consumer business, but not a priority Reuters
11:01AM  Glaxo Shifts to Boost Growth With Astra Threatening to Pass Bloomberg
05:51AM  What Should We Expect From GlaxoSmithKline plcs (LON:GSK) Earnings In The Years Ahead? Simply Wall St.
12:57AM  Rivals Help Fund Regenerons Gene-Sequencing Effort The Wall Street Journal
Jan-08-18 08:13PM  GSK's Redfern Says Pharma Remains Number One Priority Bloomberg Video
07:25PM  Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth Bloomberg
11:24AM  GSK CEO: Our top priority is to invest in growth in our c... CNBC Videos
08:00AM  Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company GlobeNewswire
08:00AM  Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose GlobeNewswire
08:00AM  1 Reason Dynavax Technologies Corporation Stock Soared in 2017 Motley Fool
07:00AM  Rivals Help Fund Regeneron's Gene-Sequencing Effort The Wall Street Journal
Jan-05-18 04:50PM  Outspoken biotech CEO Paul Hastings leaves Peninsula company (Video) American City Business Journals
09:35AM  Will J&J (JNJ) Continue to Tread Growth Path This Year? Zacks
09:05AM  How Did Novo Nordisks Victoza and Saxendra Perform in 3Q17? Market Realist
Jan-04-18 08:00AM  Novartis Gets Second Breakthrough Designation for Kisqali Zacks
08:00AM  Paul Stead Joins Adaptimmune as Vice President of Business Development GlobeNewswire
Jan-03-18 04:11PM  Spark, Glaxo Gene Therapies Near $1 Million Still A Bargain? Investor's Business Daily
03:23AM  5 Reasons to Pick Emergent as an Investment-Worthy Stock Zacks
03:07AM  5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now Zacks
Jan-02-18 07:01PM  U.K. Clears Glaxo's $700,000 Bubble Boy Disease Gene Therapy Bloomberg
Dec-31-17 02:15PM  3 Top Dividend Stocks With Yields Over 4% Motley Fool
11:48AM  Barron's Picks And Pans: Chevron, Corning, GlaxoSmithKline And More Benzinga
Dec-30-17 12:01AM  [$$] Glaxo: Expect a Speedy Recovery Barrons.com
Dec-28-17 12:41PM  GlaxoSmithKline Is a Massive Bargain GuruFocus.com
06:00AM  Top 5 Dividend Stocks in the FTSE for 2018 Investopedia
Dec-26-17 11:45AM  Measuring Sanofis Valuation This December Market Realist
Dec-25-17 09:47AM  Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio? Simply Wall St.
Dec-22-17 10:00AM  3 Reasons to Own Pfizer's Stock in 2018 Motley Fool
08:42AM  Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb Motley Fool
Dec-19-17 01:10PM  ETFs with exposure to GlaxoSmithKline Plc : December 19, 2017 Capital Cube
09:21AM  3 High-Yield Stocks Still Worth Buying Motley Fool
04:32AM  GSK's history spans three centuries and started in three ... CNBC Videos
Dec-18-17 05:52PM  Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31 Zacks
07:42AM  GlaxoSmithKline boosts stake in Saudi Arabia unit Reuters
Dec-17-17 03:14PM  Stocks That Fell to 3-Year Lows in the Week of Dec. 15 GuruFocus.com
Dec-14-17 09:51AM  10 Biggest Antidepressant Drug Companies In 2017 Insider Monkey
Dec-13-17 12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
09:40AM  Glaxo's Nucala Label Expansion Application Gets FDA Approval Zacks
Dec-12-17 11:55AM  GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US PR Newswire
Dec-11-17 05:00AM  Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer Bloomberg
Dec-08-17 12:57PM  ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017 Capital Cube
10:03AM  GlaxoSmithKline's Rockville chief lays out priorities for 2018 American City Business Journals
Dec-06-17 04:23PM  Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches Investor's Business Daily
10:30AM  Analysts Recommendations for GlaxoSmithKline in November 2017 Market Realist
10:13AM  Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time' Barrons.com
09:01AM  GlaxoSmithKlines Consumer Healthcare Business in 3Q17 Market Realist
07:31AM  GlaxoSmithKlines Vaccines Business in 3Q17 Market Realist
07:21AM  GSK, other drugmakers bet on post-Brexit UK science Reuters
Dec-05-17 08:03PM  PRESS DIGEST- Financial Times - Dec 6 Reuters
07:01PM  Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments Bloomberg
06:26PM  Australian watchdog takes GlaxoSmithKline, Novartis units to court Reuters
03:23PM  GlaxoSmithKline and the Dividend Mirage GuruFocus.com
03:15PM  Glaxo's Karenann Terrell Enlists AI in Understanding HIV Patients The Wall Street Journal
10:31AM  GlaxoSmithKlines Global Pharmaceuticals Business in 3Q17 Market Realist
09:02AM  GlaxoSmithKlines HIV Business in 3Q17 Market Realist
07:32AM  GlaxoSmithKlines Pharmaceuticals Business in 3Q17 Market Realist
06:51AM  Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation Simply Wall St.
Dec-04-17 10:33AM  GlaxoSmithKlines Business Segments in 3Q17 Market Realist
09:04AM  GlaxoSmithKlines Quarterly Revenues for 3Q17 Market Realist
07:35AM  GlaxoSmithKlines Valuation in November 2017 Market Realist
Dec-02-17 10:36AM  Is a Dividend Cut Coming From GlaxoSmithKline plc? Motley Fool
Dec-01-17 05:58PM  3 Drug/Biotech Stocks in Focus on World AIDS Day Zacks
04:35PM  How UTHRs Remodulin, Adcirca, and Unituxin Performed in 3Q17 Market Realist
02:11PM  Gauging Novartiss Valuation This November Market Realist
08:18AM  Glaxo Begins Phase III Study on Injection to Prevent HIV Zacks
Nov-30-17 02:33PM  COMM 2015-LC19 Mortgage Trust -- Moody's Affirms Six Classes of COMM 2015-LC19 Moody's
09:19AM  Glaxo Stock Down So Far This Year: Is a Reversal in Store? Zacks
06:02AM  Better Buy: GlaxoSmithKline plc vs. Pfizer Motley Fool
02:49AM  GSK starts big African study of injectable drug to prevent HIV Reuters
Nov-29-17 09:55AM  Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA Zacks
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc has a strategic drug discovery collaboration with Exscientia Limited to discover novel and selective small molecules for up to 10 disease-related targets across various therapeutic areas; and a collaboration agreement with Oklahoma Medical Research Foundation for the discovery, development, and commercialization of therapies to prevent organ damage and death caused by acute pancreatitis, lung injury, and trauma conditions. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerNov 06Buy14.00428,5715,999,9941,854,006Nov 07 07:42 PM